Skip to content
The Policy VaultThe Policy Vault

Rydapt (midostaurin) — Medica

Acute myeloid leukemia

Initial criteria

  • age ≥ 18 years
  • disease is FLT3 mutation-positive as detected by an approved test

Approval duration

1 year